Adam R. Kalbermatten

Insider · Chief Commercial Officer · KRMD

Adam R. Kalbermatten files insider transactions with the SEC as a chief commercial officer of KORU Medical Systems. We hold 2 disclosed purchases and sales filed since 11 August 2025, 2 of them in the last 90 days.

Files forKRMD
Disclosed buys and sells2 in all, 2 in the last 90 days
Last disclosure9 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed

Filed 28 July 2025 — 8 September 2026Chief Commercial Officer · KORU Medical Systems 15 Form 4 lines · source: SEC Form 4

Every transaction

15 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing

Sort byOpen-market trades only15 of 15 shown


8 Sep 2026	9 Sep 2026SEC Form 4	1 d	bought on the open market	KORU Medical Systems	32,000 shares	down −0.6%	up +0.0%
28 Jul 2026	6 Aug 2026SEC Form 4	9 d	exercised options overnot a trade	KORU Medical Systems	75,000 shares	down −21.4%	down −11.5%
28 Jul 2026	6 Aug 2026SEC Form 4	9 d	had shares withheld for taxnot a trade	KORU Medical Systems	25,483 shares	down −21.4%	down −11.5%
1 Jul 2026	13 Jul 2026SEC Form 4	12 d	was grantednot a trade	KORU Medical Systemsderivative	284,091 shares	down −28.4%	down −25.5%
1 Jul 2026	2 Jul 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	286,697 shares	down −28.4%	down −29.8%
11 Jun 2026	15 Jun 2026SEC Form 4	4 d	bought on the open market	KORU Medical Systems	5,000 shares	down −21.3%	down −18.6%
11 Jun 2026	15 Jun 2026SEC Form 4	4 d	bought on the open market	KORU Medical Systems	7,500 shares	down −21.3%	down −18.6%
17 Mar 2026	18 Mar 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	45,098 shares	down −26.2%	down −27.6%
17 Mar 2026	18 Mar 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	45,098 shares	down −26.2%	down −27.6%
17 Mar 2026	18 Mar 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	67,779 shares	down −26.2%	down −27.6%
17 Mar 2026	18 Mar 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	45,098 shares	down −26.2%	down −27.6%
17 Mar 2026	18 Mar 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	45,098 shares	down −26.2%	down −27.6%
17 Mar 2026	18 Mar 2026SEC Form 4	1 d	was grantednot a trade	KORU Medical Systemsderivative	67,779 shares	down −26.2%	down −27.6%
1 Aug 2025	11 Aug 2025SEC Form 4	10 d	was grantednot a trade	KORU Medical Systemsderivative	600,000 shares	down −9.5%	down −22.0%
28 Jul 2025	11 Aug 2025SEC Form 4	14 d	was grantednot a trade	KORU Medical Systems	300,000 shares	down −7.6%	down −22.0%

Both percentages are the stock’s move, not Adam R. Kalbermatten’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 15 of the 15 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.